7ztl | pdb_00007ztl
Crystal structure of a covalently linked Aurora-A N-Myc complex
Structural highlights
DiseaseMYCN_HUMAN Unilateral retinoblastoma;Neuroblastoma;Feingold syndrome type 1. Amplification of the N-MYC gene is associated with a variety of human tumors, most frequently neuroblastoma, where the level of amplification appears to increase as the tumor progresses.[1] The disease is caused by mutations affecting the gene represented in this entry. FunctionMYCN_HUMAN Positively regulates the transcription of NCYM in neuroblastoma cells (PubMed:24391509).[2] Publication Abstract from PubMedFormation of the Aurora-A-MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be ;undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A-MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A-MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders. Crystal structure of a covalently linked Aurora-A-MYCN complex.,Diebold M, Schonemann L, Eilers M, Sotriffer C, Schindelin H Acta Crystallogr D Struct Biol. 2023 Jan 1;79(Pt 1):1-9. doi: , 10.1107/S2059798322011433. Epub 2023 Jan 1. PMID:36601802[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||||
